IL-2 antibodies in type 1 diabetes and during IL-2 therapy

被引：6

作者：

Churlaud, Guillaume ^{[1
,2
,3
]}

Rosenzwajg, Michelle ^{[1
,2
,3
]}

Cacoub, Patrice ^{[1
,2
,3
,4
]}

Saadoun, David ^{[1
,2
,3
,4
]}

Valteau-Couanet, Dominique ^{[5
]}

Chaput, Nathalie ^{[6
,7
,8
]}

Pugliese, Alberto ^{[9
,10
,11
]}

Klatzmann, David ^{[1
,2
,3
]}

机构：

[1] Grp Hosp Pitie Salpetriere, AP HP, Biotherapy CIC BTi, Paris, France

[2] Inflammat Immunopathol Biotherapy Dept i2B, Paris, France

[3] Sorbonne Univ, INSERM, Immunol Immunopathol Immunotherapy, 83 Bd Hop, F-75651 Paris, France

[4] Grp Hosp Pitie Salpetriere, AP HP, Dept Internal Med & Clin Immunol, Natl Reference Ctr Autoimmune Syst & Rare Dis, Paris, France

[5] Gustave Roussy, Dept Pediat, Villejuif, France

[6] Inst Gustave Roussy, CNRS, UMS 3655, Inst Gustave Roussy,Lab Immunomonitoring Oncol, Villejuif, France

[7] INSERM, US23, Villejuif, France

[8] Univ Paris Sud, UFR Pharm, Chatenay Malabry, France

[9] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA

[10] Univ Miami, Miller Sch Med, Dept Med, Div Endocrinol & Metab, Miami, FL 33136 USA

[11] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA

来源：

DIABETOLOGIA | 2018年 / 61卷 / 09期

关键词：

Autoantibodies; Autoimmune disease; Autoimmunity; IL-2; Type; 1; diabetes; LOW-DOSE INTERLEUKIN-2; BINDING; PHASE; SERA;

D O I：

10.1007/s00125-018-4649-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2066 / 2068

页数：3

共 10 条

[1] Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial
Hartemann, Agnes
Bensimon, Gilbert
Payan, Christine A.
Jacqueminet, Sophie
Bourron, Olivier
Nicolas, Nathalie
Fonfrede, Michele
Rosenzwajg, Michelle
Bernard, Claude
Klatzmann, David
[J]. LANCET DIABETES & ENDOCRINOLOGY, 2013, 1 (04) : 295 - 305
[2] The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
Klatzmann, David
Abbas, Abul K.
[J]. NATURE REVIEWS IMMUNOLOGY, 2015, 15 (05) : 283 - 294
[3] Autoantibody binding in liquid phase to IL-2 in human sera is not type 1 diabetes specific
Marzinotto, Ilaria
Liberati, Daniela
Brigatti, Cristina
Bonfanti, Riccardo
Stabilini, Angela
Monti, Paolo
Bosi, Emanuele
Piemonti, Lorenzo
Lampasona, Vito
[J]. DIABETOLOGIA, 2017, 60 (09) : 1834 - 1835
[4] Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis
Meager, A
Wadhwa, M
Dilger, P
Bird, C
Thorpe, R
Newsom-Davis, J
Willcox, N
[J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 132 (01) : 128 - 136
[5] Loss of immune tolerance to IL-2 in type 1 diabetes
Perol, Louis
Lindner, John M.
Caudana, Pamela
Nunez, Nicolas Gonzalo
Baeyens, Audrey
Valle, Andrea
Sedlik, Christine
Loirat, Delphine
Boyer, Olivier
Creange, Alain
Cohen, Jose Laurent
Rogner, Ute Christine
Yamanouchi, Jun
Marchant, Martine
Leber, Xavier Charles
Scharenberg, Meike
Gagnerault, Marie-Claude
Mallone, Roberto
Battaglia, Manuela
Santamaria, Pere
Hartemann, Agnes
Traggiai, Elisabetta
Piaggio, Eliane
[J]. NATURE COMMUNICATIONS, 2016, 7
[6] Treatment-induced antibodies to interleukin-2
Prummer, O
[J]. BIOTHERAPY, 1997, 10 (01) : 15 - 24
[7] Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients
Rosenzwajg, Michelle
Churlaud, Guillaume
Mallone, Roberto
Six, Adrien
Derian, Nicolas
Chaara, Wahiba
Lorenzon, Roberta
Long, S. Alice
Buckner, Jane H.
Afonso, Georgia
Pham, Hang-Phuong
Hartemann, Agnes
Yu, Aixin
Pugliese, Alberto
Malek, Thomas R.
Klatzmann, David
[J]. JOURNAL OF AUTOIMMUNITY, 2015, 58 : 48 - 58
[8] Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
Saadoun, David
Rosenzwajg, Michelle
Joly, Florence
Six, Adrien
Carrat, Fabrice
Thibault, Vincent
Sene, Damien
Cacoub, Patrice
Klatzmann, David
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (22) : 2067 - 2077
[9] INTERLEUKIN-A BINDING-PROTEINS IN SERA FROM NORMAL SUBJECTS AND MULTIPLE-SCLEROSIS PATIENTS
TROTTER, JL
DAMICO, CA
TROTTER, AL
COLLINS, KG
CROSS, AH
[J]. NEUROLOGY, 1995, 45 (11) : 1971 - 1974
[10] High avidity cytokine autoantibodies in health and disease: Pathogenesis and mechanisms
Watanabe, Masato
Uchida, Kanji
Nakagaki, Kazuhide
Trapnell, Bruce C.
Nakata, Koh
[J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2010, 21 (04) : 263 - 273

← 1 →